Revenue
2020
2021
2022
2023
2024
Inhibikase Therapeutics, Inc. (IKT)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M | $698,468 |
| Research & development | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M | $893,802 |
| Operating income | −$52.0M | −$28.6M | −$20.1M | −$18.1M | −$14.8M | −$2.8M |
| Net income | −$48.3M | −$27.5M | −$19.0M | −$18.1M | −$14.8M | −$2.8M |
| Basic EPSper diluted share | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$0.81 | -$0.35 |
| Diluted EPSper diluted share | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$0.81 | -$0.35 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 21, 2025Form 4 | SANDS FRANK M. +2TenPercentOwner | BuyCommon Stock | 2.07M | $1.45 | $3.00M | 13.02M |
| Oct 21, 2024Form 4 | Bellini RobertoDirector | BuyCommon Stock · indirect | 1.46M | $1.37 | $2.00M | 1.46M |
| Oct 21, 2024Form 4 | Kush ArvindDirector | BuyCommon Stock | 145.0K | $1.37 | $198.7K | 145.0K |
| Oct 21, 2024Form 4 | Munshi AmitDirector | BuyCommon Stock · indirect | 365.0K | $1.37 | $500.1K | 365.0K |